Best Selling US Drugs in 2023 11 Skyrizi $10.1 billion 10 Dupixent $11.5 b 9 Biktarvy $13.15 b 8 Mounjaro $13.16 b 7 Keytruda $15.4 b 6 Stelara $15.87 b 5 Jardiance $15.89 b 4 Trulicity $16.3 b 3 Eliquis $22.1 b 2 Humira $35.3 b 1 Ozempic $38.6 b https://t.co/tiEwqyTB6D https://t.co/xghijiRFtW

384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/D7n3ZpJURH https://t.co/vJcFgRcbx4

NON-treatment of 18,318 VA pts (RA, SpA, PsA) = 41% not Rx DMARDs w/in 12 mos of Dx. Signif higher odds if Black (HR 1.13), Hispanic (1.14), Charlson Comorbidity ≥2 (1.15), opiate use (1.09). DMARD use ^ if married, w/ erosions, female MD, Rheum Dx https://t.co/TaYC27oIOz https://t.co/qjfAGI5L5g

Mayo Derm Study of 335 #SLE pts: 231 w/ skin manifestations. LE specific skin Dz signif assoc w/ photosensitivity, SM & U1RNP Abs. Pts w/ 2–4 mucocutaneous ACR criteria had less cytopenia & dsDNA Abs (P=0.004), but no assoc w/ systemic Dz https://t.co/f7PEerxKZw https://t.co/9kRW724cPq

Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on: - T cells, cytokines, TLR signaling - VTE prevention - Decr CV risks - Glucose & lipid benefits - Pregnancy https://t.co/z9cooQwZux https://t.co/QumKoHgQDY

FAERS retrospective, safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa, 2.2K Bari vs bDMARDs) found JAKi had incr risk of VTE (adj ROR=2.11), CVA (ROR=1.25), IHD (1.23), edema(1.22), & tachyarrhythmias (1.15) https://t.co/Bvds4C66Nq https://t.co/Xmu8g35MXR

Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males, earlier onset/Dx, uveitis, +FHx. B27 negativity assoc w/ psoriasis, higher peripheral arthritis/disease activity, worse QOL, mobility https://t.co/ousSetEnrt https://t.co/ezSgHro8sQ

MarketScan Claims & Medicaid study of incident AS, PsA, or RA (2010–2017) that Opioid use was highly prevalent in AS (36%), PsA (30%), & RA (44%) in the year prior to Dx & during the 1st Yr. Is this PCP or Rheumatologist mismanagement? https://t.co/YsCOLZUCfS https://t.co/b33uNg6Ucx

Insurance claims data studied 7580 newly Dx RA (2018-2020) - 1998 tofacitinib vs 5582 adalimumab. After propensity matching, dyslipidemia was signif. higher w/ TOFA (HR 1.25), BUT no differences in MACE (HR 0.995) or all-cause mortality (HR, 1.4; NS) https://t.co/ZJ7uHWTycS https://t.co/A6tSm4RipS

Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures Dr. Gregory Curfman, MD writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use. https://t.co/6Ipvw7tcKr https://t.co/VNrMg88AsH

Antacids can Diminish Bone Density Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism. https://t.co/Ii8DlDgBx7 https://t.co/cWN7v7PiIf

Retrospective 170 RA pts Rx w/ IFX, ADA, & CZP shows CZP levels didnt differ w/ low or HI RF; but high basel RF linked to lower IFX & ADA drug levels, W/O DAS28 differences, but more IFX/ADA D/C w/ Hi baseline RF levels (80% vs. 75% vs. 33% CZP, p=0.002) https://t.co/OVUcKAgJ5a https://t.co/kzWd8jHXs3